Anti-Mouse CD314 (NKG2D) PE 10 ug
- Known as:
- Antibody toMouse CD314 (NKG2D) PE 10 ug
- Catalog number:
- 12-5882-63
- Category:
- -
- Supplier:
- eBioscience
- Gene target:
- Anti-Mouse CD314 (NKG2D) 10
Related genes to: Anti-Mouse CD314 (NKG2D) PE 10 ug
- Gene:
- KLRK1 NIH gene
- Name:
- killer cell lectin like receptor K1
- Previous symbol:
- D12S2489E
- Synonyms:
- NKG2D, KLR, NKG2-D, CD314
- Chromosome:
- 12p13.2
- Locus Type:
- gene with protein product
- Date approved:
- 2003-12-12
- Date modifiied:
- 2016-10-05
Related products to: Anti-Mouse CD314 (NKG2D) PE 10 ug
Related articles to: Anti-Mouse CD314 (NKG2D) PE 10 ug
- The cellular immune response underlying post-injury multiple organ dysfunction syndrome (MODS) remains incompletely described. We hypothesized that early perturbations in innate lymphocyte behavior are critical to the development of MODS in trauma patients. To address this, we examined lymphocyte subsets in a prospective cohort of major trauma patients recruited at a single major trauma hospital. Circulating lymphocytes were profiled with flow cytometry in serial samples drawn within the hyperacute (≤2 h) and acute (24 h, 72 h) post-injury periods. Plasma levels of specific mediators derived from innate lymphocytes were also measured in a larger cohort. We observed a marked hyperacute increase in circulating NK (particularly the CD56 subset) and Vδ1 cells that were associated with MODS or early mortality. Absolute counts of NK activation markers CD69 and NKG2D were also higher in patients with adverse outcomes, although the proportion of NK cells expressing NKG2D was reduced. Exploratory cluster analyses of NK activating and inhibiting receptors identified patient groups with differing injury characteristics and outcomes. In plasma, patients who developed MODS had significantly higher levels of NK-associated cytotoxic mediators and cytokines. Collectively, these data indicate a specific pattern of hyperacute NK cell activation after major trauma that is characterized by a pattern consistent with cytotoxic lymphocyte activation and is associated with clinical outcome. - Source: PubMed
Publication date: 2026/08/24
Shepherd Joanna MGibb Lucy RTorrance Hew D TManson JoannaPennington Daniel JVulliamy PaulBrohi Karim - Delayed graft function after kidney transplant is associated with increased acute rejection rates and poorer long-term outcomes. It is significantly more prevalent in recipients of deceased than living donor kidneys due to increased ischemia-reperfusion injury associated with prolonged warm and cold ischemic times. Although specific immune populations are associated with ischemia-reperfusion injury and delayed graft function, the precise cellular circuits distinguishing deceased from living donor transplants, as well as the donor and recipient-derived immune programs involved in early immunological responses, have not been defined at cellular resolution. - Source: PubMed
Publication date: 2026/09/22
Mak Martin LMurphy Julia MMathews Jessica ASu ShenghuiKonvalinka AnaEpelman SlavaCrome Sarah Q - Systemic lupus erythematosus (SLE) is a complex autoimmune disease characterised by substantial variability in clinical presentations and disease severity. This study aims to investigate the molecular and cellular mechanisms underlying distinct SLE Disease Activity Index (SLEDAI)-defined disease states of SLE and to identify potential prognostic biomarkers and therapeutic targets associated with heightened inflammatory activity. - Source: PubMed
Publication date: 2026/09/12
Shen ChenGuo MingzheHuang JianZheng HuiwenYu Gang - The use of natural killer (NK) cells for the treatment of solid tumors such as cholangiocarcinoma has been hindered by challenges related to cell production, persistence and trafficking, as well as by reduced efficacy within an immunosuppressive tumor microenvironment. Antitumor immunity can be reduced by the interaction of NK cell expressed programmed cell death protein 1 (PD1) with ligands on tumor and other cells within the tumor microenvironment. The antitumor effect of NK cells is enhanced in cells engineered to express a truncated PD1 without an intracellular domain. The cytolytic potential and therapeutic efficacy of extracellular vesicles (EVs) derived from human NK cells expressing truncated PD1 was evaluated as a cell-free therapeutic to overcome some limitations faced by cell therapies. We demonstrate the feasibility of efficient expansion, production and isolation of therapeutic vesicles from human NK cell lines and from engineered NK92 cells expressing truncated PD1. The cytotoxic efficacy of these therapeutic vesicles was validated in both monolayer tumor cell cultures and in multicellular tumor spheroids. Concomitant administration of gemcitabine upregulated NKG2D ligands on tumor cells and increased susceptibility to NK cell and to NK cell derived EV mediated killing. These findings position engineered NK cell derived-EVs as a scalable and promising cell-free immunotherapeutic for cholangiocarcinoma. - Source: PubMed
Gondaliya PiyushZinn Dylan ASayyed Adil AliDriscoll JuliaYan Irene KMensali NadiaWälchli SébastienPatel Tushar - One of the key hallmarks of aging is the age-related decline in immune system function, accompanied by a chronic low-grade inflammation, or "inflammaging". Simultaneously, a reduced capacity of immune cells to recognize and eliminate pathogens, along with immune exhaustion, is also defined as a sign of aging. Cynomolgus macaques () belong to a group of non-human primates evolutionarily close to humans and are often used for preclinical research. - Source: PubMed
Publication date: 2026/08/13
Petrova Viktoria MBulgin Dmitry VRadomskaya Elena YuShevelov Vsevolod AZhukova Darya SChzhu Olga PManakhov Andrey DPopov Alexander VRybtsov Stanislav A